Global Thymus CancerMarket – Overview
Thymus gland is a soft lymphoid organ situated between the lungs and behind the breastbone. The main function of the thymus gland is secretion of hormone thymosin. T cells or T lymphocytes are matured by the hormone thymosin. These T cells are type of white blood cells and help body fight infections. Thymus cancer can be classified into two types: Thymoma and Thymic carcinoma. Thymoma is a condition where the cancerous cells have similar appearance as normal thymus cells, whereas, thymic carcinoma cells possess different appearance. Thymic cancer can be either benign or malignant, depending on their penetration in other tissues and organs. WHO segmented Thymoma into 6 different types based on the appearance of tumour cell shape: type A, type AB, type B1, type B2, type B3 and type C (Thymic Carcinoma). Thymoma is usually coupled with other autoimmune diseases like myasthenia gravis, thyroiditis and rheumatoid arthritis. Thymus cancer can be diagnosed with chest X-rays, CT Scans and biopsy and can be removed surgically if benign. Malignant Thymus cancer can be treated with Chemotherapy. Thymus cancer is a rare cancer and according to American cancer society, there are approximately 400 cases of thymus cancer every year.
Thymus cancer market size is likely to grow with increasing prevalence of thymic cancer. Thymic cancer is mostly found in age group of 40-60 years, hence with rising older population is likely to enhance the growth of thymus cancer market. Additionally, growing demand for technological advancements and innovative treatments along with growing government initiatives is likely to drive the global thymus market. However expensive treatment, and the side effects related to the treatment of thymus cancer are likely to affect the growth of thymus cancer market.
To get sample copy of Report Click Here @ https://www.marketresearchfuture.com/sample_request/1550 .
Astellas Pharma Inc, Cellceutix Corporation, Amgen Inc., Astrazeneca, Celgene Corporation, , Eli Lilly and company, Johnson & Johnson services Inc., Merck & Co. Inc., Novartis Pharmaceuticals, Onxeo SA, Pfizer Inc., Bristol-Myers Squibb, Sumitomo Dainippon Pharma Co. Ltd., Takeda pharmaceutical company, Taiwan Liposome Company Ltd., Tiziana Life Sciences Plc., Roche, Glenmark, AbbVie, Sun Pharmaceuticals industries Ltd., PharmaCyte Biotech, Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Daiichi Sankyo Cancer Enterprise GlaxoSmithKline plc. And others are some of the key players at the forefront of competition in the Global Thymus Cancer Market and are profiled in MRFR Analysis.
Thymus Cancer Market by types:
- Type A
- Type AB
- Type B1
- Type B2
- Type B3
- thymic carcinoma
Thymus Cancer Market by treatment:
Thymus Cancer Market by care centers:
- Diagnostic centers
- Research laboratories
Global Thymus Cancer Market – Competitive Analysis
Founded in 1980, Celgene Corporation is a biopharmaceutical company which develops drugs for cancer and inflammatory diseases. Celgene Corporation in December 2017, launched a program called Celgene Cancer Care Links. This is a support program launched to help all cancer patients in under developed countries. These support centres are built for early diagnosis, prevention and treatments to improve patient’s lives. Celgene Corporation acquired Juno therapeutics in 2015 to develop better immuno-oncology therapies. This also increases the global footprint of celgene Corporation.
Furthermore, Novartis Pharmaceuticals is an organization that develops and manufactures drugs for various diseases and conditions. Novartis pharmaceuticals is carrying out clinical trials to check the efficacy of Octreotide treatment in patients suffering from primary inoperable thymoma.
Pfizer Inc. the world’s leading Biopharmaceutical Company based in New York City, US. The company in February 2015, discovered that Sunitinib, a tyrosine kinase inhibitor slowed the progression of thymus cancer in patients. Tyrosine kinase pathways like VEGFR, KIT, and PDGFR, stimulate cell proliferation which leads to thymus carcinomas. This drug hinders these pathways and therefore stops the progression of thymus cancer. This drug will offer second line treatment to patients suffering from thymus cancer. Gregory Riely, MD, PhD, specializes in treating thymic tumors, is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, US, stated that no other drug, but Sunitinib was found to be so active against the thymus cancer.
Thymus cancer market is divided into five segments: North America (U.S. and Canada), Latin America (Mexico, Brazil, Peru, Chile, and others), Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg), Eastern Europe (Poland and Russia), Asia Pacific (China, India, Japan, Australia, and New Zealand), Middle East and Africa (GCC, Southern Africa, and North Africa). The market is dominated by North America due increasing rate of Allergy cases which leads to Angioedema. The second largest market is Europe. Thymus cancer is rare, but genetic mutations and other environmental factors can give rise to this condition.
Access Complete Report @ https://www.marketresearchfuture.com/reports/thymus-cancer-market-1550 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar